Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.57 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.57 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.57 |
| ▸ | TLR2 | O60603 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.55 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7772568 | 1.00 | ENPP2 (0.65) | ENPP2KDM4ETP53CYP3A4ALDH1A1 | |
| Syringol SCHEMBL27708099 | 0.84 | KDM4E (0.70) | ENPP2KDM4ETP53CYP3A4ALDH1A1 | |
| SCHEMBL25345985 | 0.83 | ENPP2 (0.60) | ENPP2KDM4ETP53CYP3A4ALDH1A1 | |
| SCHEMBL7772570 | 0.82 | ENPP2 (0.50) | ENPP2KDM4ETP53CYP3A4ALDH1A1 | |
| SCHEMBL7772580 | 0.81 | KDM4E (0.50) | ENPP2KDM4ETP53CYP3A4ALDH1A1 | |
| Syringol SCHEMBL156388 | 0.81 | KDM4E (0.80) | ENPP2KDM4ETP53CYP3A4ALDH1A1 | |
| SCHEMBL29957360 | 0.81 | ENPP2 (0.63) | ENPP2KDM4ETP53CYP3A4ALDH1A1 | |
| SCHEMBL23807 | 0.79 | ENPP2 (1.00) | ENPP2KDM4ETP53CYP3A4ALDH1A1 | |
| SCHEMBL29466484 | 0.79 | ENPP2 (1.00) | ENPP2KDM4ETP53CYP3A4ALDH1A1 | |
| Syringol SCHEMBL6049240 | 0.79 | KDM4E (0.76) | ENPP2KDM4ETP53CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688750-A1 | SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-20240336572-A1 | SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF | PFIZER INC. (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024209363-A1 | SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS | PFIZER INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3426653-B1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20200299305-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA | 2020-09-24 | — | — | US | disclosed |
| US-20190071450-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA (CH) | 2019-03-07 | — | — | US | disclosed |
| EP-2178886-A1 | MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-04-28 | — | — | EP | disclosed |
| US-20090048239-A1 | Therapeutic compounds | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| WO-2009010783-A1 | MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010785-A1 | MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-01-22 | — | — | WO | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-6541490-B1 | Treating ischemia or reoxygenation injury; preparation from a bipyridine, a benzeneboronic acid and a manganese salt | EUKARION, INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1119573-A2 | BIPYRIDINE MANGANESE COMPLEXES | EUKARION, INC. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6177419-B1 | ANTIOXIDANT CHELATE COMPOUNDS FOR PREVENTING OXYGEN FREE RADICAL-ASSOCIATED DISEASES IN MAMMALS; NEUROPROTECTANTS, SUPEROXIDE DISMUTASE (SOD), CATALASE (CAT) AND/OR PEROXIDASE (POD) MIMETICS | EUKARION, INC. | 2001-01-23 | — | — | US | disclosed |
| WO-2000009512-A2 | BIPYRIDINE MANGANESE COMPLEXES | EUKARION, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336572-A1 | SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF | PRKAG3, PRKAG1, PRKAG2 | ENPP2 2307/4885KDM4E 3329/4885TP53 999/4885 |
| US-20190071450-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | SNCA, PARK7, NLN | ENPP2 728/4885KDM4E 4478/4885TP53 2659/4885 |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | ENPP2 1072/4885KDM4E 4608/4885TP53 4607/4885 |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | ENPP2 1072/4885KDM4E 4608/4885TP53 4607/4885 |
| US-20200299305-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | SNCA, PARK7, NLN | ENPP2 728/4885KDM4E 4478/4885TP53 2659/4885 |
| US-20090048239-A1 | Therapeutic compounds | RRP1B, RCE1, CTSZ | ENPP2 1409/4885KDM4E 1806/4885TP53 1260/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | ENPP2 1072/4885KDM4E 4608/4885TP53 4607/4885 |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | ENPP2 536/4885KDM4E 2400/4885TP53 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.